Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Case and Review

Two Cases of Interferon-Alpha-Induced Sarcoidosis Koebnerized along Venous Drainage Lines: New Pathogenic Insights and Review of the Literature of Interferon-Induced Sarcoidosis

Buss G.a · Cattin V.b · Spring P.b · Malinverni R.c · Gilliet M.b

Author affiliations

aDivision of Immunology and Allergology and bDepartment of Dermatology, University Hospital Center and University of Lausanne, Lausanne, and cInternal Medicine Department, Hôpital Neuchâtelois, Neuchâtel, Switzerland

Related Articles for ""

Dermatology 2013;226:289-297

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Case and Review

Received: August 10, 2012
Accepted: November 26, 2012
Published online: July 23, 2013
Issue release date: September 2013

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 1

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

Sarcoidosis is a systemic granulomatous disorder of unknown origin commonly affecting the lung, the lymphoid system and the skin. We report here two cases of cutaneous sarcoidosis in two former intravenous drug users following interferon (IFN)-α and ribavirin therapy for chronic hepatitis C. Both patients developed skin sarcoidosis along venous drainage lines of both forearms, coinciding with the areas of prior drug injections. The unique distribution of the skin lesions suggests that tissue damage induced by repeated percutaneous drug injections represents a trigger for the local skin manifestation of sarcoidosis. Interestingly, skin damage was recently found to induce the local expression IFN-α, a well-known trigger of sarcoidosis in predisposed individuals. Here we review the literature on sarcoidosis elicited in the context of IFN-α therapy and propose a new link between the endogenous expression of IFN-α and the induction of disease manifestations in injured skin.

© 2013 S. Karger AG, Basel


References

  1. Costabel U, Hunninghake GW: ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 1999;14:735-737.
  2. Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G: Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat 1997;4:185-191.
  3. Holmes J, Lazarus A: Sarcoidosis: extrathoracic manifestations. Dis Mon 2009;55:675-692.
  4. Martins EV, Gaburri AK, Gaburri D, Sementilli A: Cutaneous sarcoidosis: an uncommon side effect of pegylated interferon and ribavirin use for chronic hepatitis C. Case Rep Gastroenterol 2009;3:366-371.
  5. Ubina-Aznar E, Fernandez-Moreno N, Rivera-Irigoin R, Navarro-Jarabo JM, Garcia-Fernandez G, Perez-Aisa A, Vera-Rivero F, Fernandez-Perez F, Moreno-Mejias P, Mendez-Sanchez I, de Sola-Earle C, Sanchez-Cantos A: Pulmonary sarcoidosis associated with pegylated interferon in the treatment of chronic hepatitis C (in Spanish). Gastroenterol Hepatol 2005;28:450-452.
  6. Londner C, Zendah I, Freynet O, Carton Z, Dion G, Nunes H, Valeyre D: Treatment of sarcoidosis (in French). Rev Med Interne 2011;32:109-113.
  7. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-755.
  8. Robinson BW, McLemore TL, Crystal RG: Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985;75:1488-1495.
  9. Baumer I, Zissel G, Schlaak M, Muller-Quernheim J: Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1997;16:171-177.
  10. Parronchi P, Mohapatra S, Sampognaro S, Giannarini L, Wahn U, Chong P, Mohapatra S, Maggi E, Renz H, Romagnani S: Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol 1996;26:697-703.
  11. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T: Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999;30:376-382.
  12. Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T, Janosch A, Schetter C, Krieg AM: Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother 2004;48:2314-2317.
  13. Hurst EA, Mauro T: Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 2005;141:865-868.
  14. Blum L, Serfaty L, Wattiaux MJ, Picard O, Cabane J, Imbert JC: Nodules hypodermiques sarcoïdosiques au cours d'une hépatite virale C traitée par interféron alpha 2b. Rev Med Interne 1993;14:1161.
    External Resources
  15. Fantini F, Padalino C, Gualdi G, Monari P, Giannetti A: Cutaneous lesions as initial signs of interferon alpha-induced sarcoidosis: report of three new cases and review of the literature. Dermatol Ther 2009;22(suppl 1):S1-S7.
  16. Cogrel O, Doutre MS, Marliere V, Beylot-Barry M, Couzigou P, Beylot C: Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases. Br J Dermatol 2002;146:320-324.
  17. Ramos-Casals M, Mana J, Nardi N, Brito-Zeron P, Xaubet A, Sanchez-Tapias JM, Cervera R, Font J, Group HS: Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 2005;84:69-80.
  18. Pelletier F, Manzoni P, Jacoulet P, Humbert P, Aubin F: Pulmonary and cutaneous sarcoidosis associated with interferon therapy for melanoma. Cutis 2007;80:441-445.
    External Resources
  19. Atluri D, Iduru S, Veluru C, Mullen K: A levitating tattoo in a hepatitis C patient on treatment. Liver Int 2010;30:583-584.
  20. Toulemonde A, Quereux G, Dreno B: Sarcoidosis granuloma on a tattoo induced by interferon alpha (in French). Ann Dermatol Venereol 2004;131:49-51.
  21. Perera GK, Calonje E: Systemic sarcoidosis presenting in a tattooed man undergoing treatment for hepatitis C. Clin Exp Dermatol 2006;31:387-389.
  22. Descamps V, Landry J, Frances C, Marinho E, Ratziu V, Chosidow O: Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases. Dermatology 2008;217:81-84.
  23. Shuja F, Kavoussi SC, Mir MR, Jogi RP, Rosen T: Interferon induced sarcoidosis with cutaneous involvement along lines of venous drainage in a former intravenous drug user. Dermatol Online J 2009;15:4.
    External Resources
  24. Lee YB, Lee JI, Park HJ, Cho BK, Oh ST: Interferon-alpha induced sarcoidosis with cutaneous involvement along the lines of venous drainage. Ann Dermatol 2011;23:239-241.
  25. Marcoval J, Mana J, Moreno A, Gallego I, Fortuno Y, Peyri J: Foreign bodies in granulomatous cutaneous lesions of patients with systemic sarcoidosis. Arch Dermatol 2001;137:427-430.
    External Resources
  26. Perez-Gala S, Delgado-Jimenez Y, Goiriz R, Fernandez-Herrera J, Fraga J, Garcia-Diez A: Cutaneous sarcoidosis limited to scars following pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C. J Eur Acad Dermatol Venereol 2007;21:393-394.
  27. Gregorio J, Meller S, Conrad C, Di Nardo A, Homey B, Lauerma A, Arai N, Gallo RL, Digiovanni J, Gilliet M: Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J Exp Med 2010;207:2921-2930.
  28. Gilliet M, Cao W, Liu YJ: Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008;8:594-606.
  29. Roche B, Samuel D: Transplantation: steroid use in HCV-infected liver transplant recipients. Nat Rev Gastroenterol Hepatol 2009;6:198-200.
  30. Oudghiri B, Benzagmout M, Boujraf S, Belahcen F, Ibrahimi A: Multisystem sarcoidosis in a patient on interferon-alpha therapy for chronic hepatitis C. J Glob Infect Dis 2012;4:128-131.
  31. Benzagmout M, Oudghiri B, Boujraf S, Chakour K, Chaoui Mel F: Fatal neurosarcoidosis induced by interferon alpha treatment in chronic hepatitis C. Neurol India 2010;58:949-950.
  32. Abdi EA, Nguyen GK, Ludwig RN, Dickout WJ: Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 1987;59:896-900.
  33. Liozon E, Cransac M, Remenieras L, Cartry-Thomas I, Vovor A, Bordessoule D: La sarcoïdose: une nouvelle complication de traitement par l'interféron alpha. Rev Med Interne 1993;14:1160.
    External Resources
  34. Ohhata I, Ochi T, Kurebayashi S, Masutani H, Kikui M: A case of subcutaneous sarcoid nodules induced by interferon-alpha (in Japanese). Nihon Kyobu Shikkan Gakkai Zasshi 1994;32:996-1000.
    External Resources
  35. Bobbio-Pallavicini E, Valsecchi C, Tacconi F, Moroni M, Porta C: Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis 1995;12:140-142.
    External Resources
  36. Nakajima M, Kubota Y, Miyashita N, Niki Y, Matsushima T, Manabe T: Recurrence of sarcoidosis following interferon alpha therapy for chronic hepatitis C. Intern Med 1996;35:376-379.
  37. Teragawa H, Hondo T, Takahashi K, Watanabe H, Ohe H, Hattori N, Watanabe Y, Amano H, Hino F, Ohbayashi M, Urushihara T, Yonehara S: Sarcoidosis after interferon therapy for chronic active hepatitis C. Intern Med 1996;35:19-23.
  38. Otte HG, Hartig C, Stadler R: Sarcoidosis in interferon-alpha therapy (in German). Hautarzt 1997;48:482-487.
  39. Hoffmann RM, Jung MC, Motz R, Gossl C, Emslander HP, Zachoval R, Pape GR: Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998;28:1058-1063.
  40. Kikawada M, Ichinose Y, Kunisawa A, Yanagisawa N, Minemura K, Kasuga I, Yonemaru M, Kawanishi K, Takasaki M, Toyama K: Sarcoidosis induced by interferon therapy for chronic myelogenous leukaemia. Respirology 1998;3:41-44.
  41. Mehta CL, Tyler RJ, Cripps DJ: Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. J Am Acad Dermatol 1998;39:1024-1028.
  42. Yavorkovsky LL, Carrum G, Bruce S, McCarthy PL Jr: Cutaneous sarcoidosis in a patient with Philadelphia-positive chronic myelogenous leukemia treated with interferon-alpha. Am J Hematol 1998;58:80-81.
  43. Eberlein-Konig B, Hein R, Abeck D, Engst R, Ring J: Cutaneous sarcoid foreign body granulomas developing in sites of previous skin injury after systemic interferon-alpha treatment for chronic hepatitis C. Br J Dermatol 1999;140:370-372.
  44. Pietropaoli A, Modrak J, Utell M: Interferon-alpha therapy associated with the development of sarcoidosis. Chest 1999;116:569-572.
  45. Cacoub P, Sbai A, Frances C, Genesti C, Hausfater P, Piette JC: Systemic sarcoidosis during interferon-alpha therapy for chronic hepatitis C virus infection (in French). Gastroenterol Clin Biol 2000;24:364-366.
    External Resources
  46. Savoye G, Goria O, Herve S, Riachi G, Noblesse I, Bastien L, Courville P, Lerebours E: Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C (in French). Gastroenterol Clin Biol 2000;24:679.
    External Resources
  47. Vander Els NJ, Gerdes H: Sarcoidosis and IFN-alpha treatment. Chest 2000;117:294.
  48. Pohl J, Stremmel W, Kallinowski B: Pulmonal sarcoidosis: a rare side effect of interferon-alpha treatment for chronic hepatitis C infection (in German). Z Gastroenterol 2000;38:951-955.
  49. Frankova H, Gaja A, Hejlova N: Pulmonary sarcoidosis in a patient with essential thrombocythemia treated with interferon alpha: a short case report. Med Sci Monit 2000;6:380-382.
    External Resources
  50. Fiorani C, Sacchi S, Bonacorsi G, Cosenza M: Systemic sarcoidosis associated with interferon-alpha treatment for chronic myelogenous leukemia. Haematologica 2000;85:1006-1007.
    External Resources
  51. Vallina E, Garcia Diez A, Gallego M, Villaverde P, Rippe ML, Arribas JM: A case of pulmonary sarcoidosis induced by interferon alfa treatment in a female patient with hepatitis C (in Spanish). An Med Interna 2000;17:538-539.
    External Resources
  52. Neglia V, Sookoian S, Herrera M, Abeldano A, Kien MC, Chouela E, Frider B: Development of cutaneous sarcoidosis in a patient with chronic hepatitis C treated with interferon alpha 2b. J Cutan Med Surg 2001;5:406-408.
    External Resources
  53. Miwa H, Furuya T, Tanaka S, Mizuno Y: Neurosarcoidosis associated with interferon therapy. Eur Neurol 2001;45:288-289.
  54. Krehmeier H, Egberts EH: Sarcoidosis after interferon-alpha treatment in hepatitis C (in German). Dtsch Med Wochenschr 2001;126:460.
  55. Ravenel JG, McAdams HP, Plankeel JF, Butnor KJ, Sporn TA: Sarcoidosis induced by interferon therapy. AJR Am J Roentgenol 2001;177:199-201.
  56. Husa P, Klusakova J, Jancikova J, Husova L, Horalek F: Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis B. Eur J Intern Med 2002;13:129-131.
  57. Wendling J, Descamps V, Grossin M, Marcellin P, Le Bozec P, Belaich S, Crickx B: Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C. Arch Dermatol 2002;138:546-547.
  58. Perez-Alvarez R, Perez-Lopez R, Lombrana JL, Rodriguez M, Rodrigo L: Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine. J Viral Hepat 2002;9:75-79.
  59. Nawras A, Alsolaiman MM, Mehboob S, Bartholomew C, Maliakkal B: Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferon-alpha treatment for chronic hepatitis C and review of the literature. Dig Dis Sci 2002;47:1627-1631.
  60. Noguchi K, Enjoji M, Nakamuta M, Sugimoto R, Kotoh K, Nawata H: Various sarcoid lesions in a patient induced by interferon therapy for chronic hepatitis C. J Clin Gastroenterol 2002;35:282-284.
  61. Gitlin N: Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases. Eur J Gastroenterol Hepatol 2002;14:883-885.
  62. Yamada S, Mine S, Fujisaki T, Ohnari N, Eto S, Tanaka Y: Hepatic sarcoidosis associated with chronic hepatitis C. J Gastroenterol 2002;37:564-570.
  63. Li SD, Yong S, Srinivas D, Van Thiel DH: Reactivation of sarcoidosis during interferon therapy. J Gastroenterol 2002;37:50-54.
  64. Leveque L, de Boulard A, Bielefeld P, Sgro C, Hillon P, Gabreau T, Champigneulle B, Makki H, Besancenot JF: Sarcoidosis during the treatment of hepatitis C by interferon-alpha and ribavirin: 2 cases (in French). Rev Med Interne 2001;22:1248-1252.
  65. Luchi S, Scasso A: Sarcoidosis, chronic hepatitis C and interferon-alpha: two cases. Scand J Infect Dis 2003;35:775-776.
  66. Tahan V, Ozseker F, Guneylioglu D, Baran A, Ozaras R, Mert A, Ucisik AC, Cagatay T, Yilmazbayhan D, Senturk H: Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature. Dig Dis Sci 2003;48:169-173.
  67. Rubinowitz AN, Naidich DP, Alinsonorin C: Interferon-induced sarcoidosis. J Comput Assist Tomogr 2003;27:279-283.
  68. Leclerc S, Myers RP, Moussalli J, Herson S, Poynard T, Benveniste O: Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur J Intern Med 2003;14:237-243.
  69. Tortorella C, Napoli N, Panella E, Antonaci A, Gentile A, Antonaci S: Asymptomatic systemic sarcoidosis arising 5 years after IFN-alpha treatment for chronic hepatitis C: a new challenge for clinicians. J Interferon Cytokine Res 2004;24:655-658.
  70. Salvio A, Mormile M, Giannattasio F, Varriale M, d'Errico T, Balzano B, Carratu P, Tufano G, Visconti M: Pulmonary sarcoidosis during interferon therapy: a rare or underestimated event? Ann Ital Med Int 2004;19:58-62.
    External Resources
  71. Menon Y, Cucurull E, Reisin E, Espinoza LR: Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci 2004;328:173-175.
  72. Werchniak AE, Cheng SX, Dhar AD, Klaus SN: Sarcoidosis presenting as tattoo changes in a patient undergoing treatment with interferon-alpha and ribavirin. Clin Exp Dermatol 2004;29:547-548.
  73. Marzouk K, Saleh S, Kannass M, Sharma OP: Interferon-induced granulomatous lung disease. Curr Opin Pulm Med 2004;10:435-440.
  74. Rogers CJ, Romagosa R, Vincek V: Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C. J Am Acad Dermatol 2004;50:649-650.
  75. Massaguer S, Sanchez M, Castel T: Mediastinal sarcoidosis induced by high-dose alpha-2-interferon therapy in a patient with malignant melanoma. Eur Radiol 2004;14:1716-1717.
  76. Alfageme Michavila I, Merino Sanchez M, Perez Ronchel J, Lara Lara I, Suarez Garcia E, Lopez Garrido J: Sarcoidosis following combined ribavirin and interferon therapy: a case report and review of the literature (in Spanish). Arch Bronconeumol 2004;40:45-49.
  77. Papaioannides D, Fotinou M, Korantzopoulos P, Latsi P, Sinapidis D, Akritidis N, Orphanidou D: Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. Med Sci Monit 2004;10:CS5-CS7.
    External Resources
  78. Guilabert A, Bosch X, Julia M, Iranzo P, Mascaro JM Jr: Pegylated interferon alfa-induced sarcoidosis: two sides of the same coin. Br J Dermatol 2005;152:377-379.
  79. Tsiodras S, Drimala P, Stavreas N, Dachlythras M, Alamani AM, Naoum G: Uterine sarcoidosis potentially associated with interferon-alpha use for chronic hepatitis C infection. Obstet Gynecol 2005;105:1198-1201.
    External Resources
  80. Butnor KJ: Pulmonary sarcoidosis induced by interferon-alpha therapy. Am J Surg Pathol 2005;29:976-979.
  81. Celik G, Sen E, Ulger AF, Kumbasar OO, Bozkaya H, Alper D, Karayalcin S: Sarcoidosis caused by interferon therapy. Respirology 2005;10:535-540.
  82. Hirano A, Kataoka M, Nakata Y, Takeda K, Kamao T, Hiramatsu J, Kimura G, Tanimoto Y, Kanehiro A, Tanimoto M: Sarcoidosis occurring after interferon-alpha therapy for chronic hepatitis C: report of two cases. Respirology 2005;10:529-534.
  83. Weyer P, Cummings OW, Knox KS: A 49-year-old woman with hepatitis, confusion, and abnormal chest radiograph findings. Chest 2005;128:3076-3079.
  84. Akay BN, Ekmekci P, Sanli H, Celik G, Bozdayi M: Cutaneous, pulmonary and hepatic sarcoidosis associated with autoimmune complications during interferon-alpha treatment for hepatitis C virus infection. J Eur Acad Dermatol Venereol 2006;20:442-445.
  85. Goldberg HJ, Fiedler D, Webb A, Jagirdar J, Hoyumpa AM, Peters J: Sarcoidosis after treatment with interferon-alpha: a case series and review of the literature. Respir Med 2006;100:2063-2068.
  86. Benali S, Boustière C, Castellani P, Cesari C, Jullien M, Lecomte L, Lebars O, Lambot G, Loyer R, Masseboeuf A, Perrier H, Oules V, Bourlière M: Sarcoidosis following pegylated interferon therapy: two cases (in French). Gastroenterol Clin Biol 2006;30:615-619.
    External Resources
  87. Bolukbas C, Bolukbas FF, Kebdir T, Canayaz L, Dalay AR, Kilic G, Ovunc O: Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C - a case report and review of the literature. Acta Gastroenterol Belg 2005;68:432-434.
    External Resources
  88. Doyle MK, Berggren R, Magnus JH: Interferon-induced sarcoidosis. J Clin Rheumatol 2006;12:241-248.
  89. Bonnet F, Morlat P, Dubuc J, De Witte S, Bonarek M, Bernard N, Lacoste D, Beylot J: Sarcoidosis-associated hepatitis C virus infection. Dig Dis Sci 2002;47:794-796.
  90. Godoy E, Arora K, Atten MJ, Youg S, Attar BM: Sarcoidosis induced by interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 2001;96:S202.
  91. Alazemi S, Campos MA: Interferon-induced sarcoidosis. Int J Clin Pract 2006;60:201-211.
  92. Iwashita M, Maeda T, Tagami A, Watanabe N, Takada J, Asano T, Hatakeyama H, Hayashi T, Nishiwaki S, Saito K: A case of cardiac sarcoidosis occurring during combination therapy by IFN alpha and ribavirin for chronic hepatitis C (in Japanese). Nihon Shokakibyo Gakkai Zasshi 2010;107:1319-1327.
  93. Bitetto D, Fumolo E, Fabris C, Toniutto P: Sarcoidosis or foreign-body granulomatous reaction during interferon treatment? Liver Int 2010;30:1083-1084.
  94. Meller S, Reifenberger J, Ruzicka T, Homey B: Induktion einer Sarkoidose unter Therapie mit pegyliertem Interferon-alpha2a. Hautarzt 2006;57:317-318.
  95. Honsová E, Sticová E, Sperl J: Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C - a case report (in Czech). Cesk Patol 2007;43:27-30.
    External Resources
  96. Sanchez-Ruano JJ, Artaza-Varasa T, Gomez-Rodriguez R, Gonzalez de Frutos C, Repiso-Ortega A, Alcantara-Torres M: Cutaneopulmonary sarcoidosis during pegylated interferon plus ribavirin therapy (in Spanish). Gastroenterol Hepatol 2006;29:150.
    External Resources
  97. Song K, Das K: Cutaneous sarcoidosis in a woman with chronic hepatitis C and interferon therapy: a case report. Acta Cytol 2010; 54:863-866.
    External Resources
  98. Adla M, Downey KK, Ahmad J: Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of literature. Dig Dis Sci 2008;53:2810-2812.
  99. Doycheva D, Deuter C, Stuebiger N, Zierhut M: Interferon-alpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol 2009;247:675-680.
  100. Yan KK, Dinihan I, Freiman J, Zekry A: Sarcoidosis presenting with granulomatous uveitis induced by pegylated interferon and ribavirin therapy for hepatitis C. Intern Med J 2008;38:207-210.
  101. Lopez V, Molina I, Monteagudo C, Jorda E: Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature. Int J Dermatol 2011;50:287-291.
  102. Petousi N, Thomas EC: Interferon-beta-induced pulmonary sarcoidosis in a 30-year-old woman treated for multiple sclerosis: a case report. J Med Case Rep 2012;6:344.
  103. Chakravarty SD, Harris ME, Schreiner AM, Crow MK: Sarcoidosis triggered by interferon-beta treatment of multiple sclerosis: a case report and focused literature review. Semin Arthritis Rheum 2012;42:206-212.
  104. Carbonelli C, Montepietra S, Caruso A, Cavazza A, Feo C, Menzella F, Motti L, Zucchi L: Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy. Monaldi Arch Chest Dis 2012;77:29-31.
    External Resources
  105. O'Reilly S, White A, Florian A: Mediastinal sarcoidosis in a patient receiving interferon-beta for multiple sclerosis. Chest 2005;128:450S.
  106. Novoa R, Barnadas MA, Torras X, Curell R, Alomar A: Foreign body granulomatous reaction to silica, silicone, and hyaluronic acid in a patient with interferon-induced sarcoidosis (in Spanish). Actas Dermosifiliogr 2012, E-pub ahead of print.
  107. Albaker WI: Hypercalcemia induced by interferon therapy in chronic hepatitis C. J Family Community Med 2012;19:141-144.
  108. North J, Mully T: Alpha-interferon induced sarcoidosis mimicking metastatic melanoma. J Cutan Pathol 2011;38:585-589.
  109. Morley AM, O'Sullivan E, Thaung C, Malhotra R: Sarcoid-related dacryoadenitis following treatment with interferon alpha and ribavarin for hepatitis C. Orbit 2011;30:27-29.
  110. Sionidou M, Spyratos D, Chloros D, Sichletidis L: Interferon α-induced sarcoidosis to a patient with polycythemia vera. BMJ Case Rep DOI: 10.1136/bcr.01.2011.3740.
  111. Cardoso C, Freire R, Alves A, Oliveira A: Interferon-induced sarcoidosis. BMJ Case Rep DOI: 10.1136/bcr.03.2011.3929.
  112. Gayet AR, Plaisance P, Bergmann JF, Mouly S: Development of sarcoidosis following completion of treatment for hepatitis C with pegylated interferon-{alpha}2a and ribavirin: a case report and literature review. Clin Med Res 2010;8:163-167.
  113. Heinzerling LM, Anliker MD, Muller J, Schlaeppi M, von Moos R: Sarcoidosis induced by interferon-alpha in melanoma patients: incidence, clinical manifestations, and management strategies. J Immunother 2010;33:834-839.
  114. Rodriguez-Lojo R, Almagro M, Barja JM, Pineyro F, Perez-Varela L, Del Pozo J, Yebra-Pimentel MT, Fonseca E: Subcutaneous sarcoidosis during pegylated interferon alfa and ribavirin treatment for chronic hepatitis C. Dermatol Res Pract 2010;2010:230417.
  115. Faurie P, Broussolle C, Zoulim F, Trepo C, Seve P: Sarcoidosis and hepatitis C: clinical description of 11 cases. Eur J Gastroenterol Hepatol 2010;22:967-972.
  116. Le Bras M, Hervier B, Wastiaux H, Masseau A, Durant C, Jossic F, Hamidou M: Systemic sarcoidosis after treatment with pegylated interferon-alpha (in French). Rev Med Interne 2010;31:e11-e13.
  117. Zampino MR, Corazza M, Borghi A, Marzola A, Virgili A: Hla typing in an IFN- alpha-induced scar sarcoidosis: possible pathogenetic and clinical implications. Acta Derm Venereol 2009;89:661-662.

Article / Publication Details

First-Page Preview
Abstract of Case and Review

Received: August 10, 2012
Accepted: November 26, 2012
Published online: July 23, 2013
Issue release date: September 2013

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 1

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.